Background: Risk stratification strategies for cancer therapeutics-related cardiac dysfunction
(CTRCD) rely on serial monitoring by specialized imaging, limiting their scalability …

Anthracyclines can cause cancer therapy-related cardiac dysfunction (CTRCD) that
adversely affects prognosis. Despite guideline recommendations, only half of the patients …

Background The growing awareness of cardiovascular toxicity from cancer therapies has led
to the emerging field of cardio‐oncology, which centers on preventing, detecting, and …

Importance Diagnosis of cancer therapy–related cardiac dysfunction (CTRCD) remains a
challenge. Cardiovascular magnetic resonance (CMR) provides accurate measurement of …

Background Current guidelines recommend using sequential cardiac imaging to monitor for
cancer treatment-related cardiac dysfunction (CTRCD) in patients undergoing potentially …

Background Cardiovascular disease is a leading cause of death in general population and
the second leading cause of mortality and morbidity in cancer survivors after recurrent …

Aims Cardiotoxicity is a serious side effect of anthracycline treatment, most commonly
manifesting as a reduction in left ventricular ejection fraction (EF). Early recognition and …

Background The impact of recent consensus definitions of cancer therapy–related cardiac
dysfunction (CTRCD) from the European Society of Cardiology cardio-oncology guidelines …

Cardiotoxicity is an important issue for breast cancer patients receiving anthracycline-
trastuzumab therapy in the adjuvant setting. Studies show that 3–36% of patients receiving …

Cancer-therapeutics-related cardiac dysfunction (CTRCD) is an important concern in
women receiving trastuzumab therapy for HER2+ breast cancer. However, the ability to …